A. Mathioudakis (Stockport, United Kingdom), B. Gemicioglu (Istanbul, Turkey)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial
J. Hurst (London, United Kingdom), M. Han (Ann Arbor, MI, United States of America), B. Celli (Boston, MA, United States of America), M. Bafadhel (Oxford, United Kingdom), M. Jenkins (Cambridge, United Kingdom), P. Dorinsky (Durham, NC, United States of America), M. Patel (Cambridge, United Kingdom)
|   |
Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial
K. Rabe (Grosshansdorf, Germany), G. Ferguson (Farmington Hills, MI, United States of America), M. Jenkins (Cambridge, United Kingdom), M. Patel (Cambridge, United Kingdom), P. Dorinsky (Durham, NC, United States of America)
| |
Risk factors for all-cause mortality in patients with COPD: results from the ETHOS trial
G. Ferguson (Farmington Hills, MI, United States of America), D. Singh (Manchester, United Kingdom), K. Rabe (Grosshansdorf, Germany), M. Jenkins (Cambridge, United Kingdom), M. Patel (Cambridge, United Kingdom), P. Dorinsky (Durham, NC, United States of America)
| |
The association between health-related quality of life and COPD exacerbations measured by EQ-5D-5L in the ETHOS trial
D. Jackson (Cambridge, United Kingdom), M. Jenkins (Cambridge, United Kingdom), E. De Nigris (Cambridge, United Kingdom), M. Patel (Cambridge, United Kingdom), M. Ouwens (Gothenburg, Sweden)
| |
Predicting SGRQ score based on CAT score: post-hoc analysis of the IMPACT trial
P. Jones (Brentford, United Kingdom), S. Shukla (Collegeville, United States of America), L. Tombs (London, United Kingdom), A. Ismaila (Collegeville, United States of America), A. Martin (Uxbridge, United Kingdom), D. Midwinter (Brentford, United Kingdom), I. Boucot (Brentford, United Kingdom), N. Risebrough (Toronto, Canada), C. Vogelmeier (Marburg, Germany)
| |
Factors influencing LAMA addition to COPD patients receiving ICS/LABA in clinical practice-RETRIEVE study.
S. Tryfon (Thessaloniki, Greece), G. Krommidas (Ilioupolis, Greece), A. Kapetangiorgis (Thermi, Greece), M. Bertoli (Pikermi, Greece), P. Papanastasiou (Pikermi, Greece)
| |
Lung function and reported dyspnea in Greek COPD patients under treatment with fluticasone/salmeterol FDC via Elpenhaler device with or without cardiovascular comorbidity - AEOLOS study.
S. Tryfon (Thessaloniki, Greece), P. Steiropoulos (Alexandroupolis, Greece), A. Ginis (Pikermi, Greece), M. Bertoli (Pikermi, Greece)
| |
Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial
L. Bjermer (Lund, Sweden), C. Vogelmeier (Marburg, Germany), E. Kerwin (Medford, OR, United States of America), I. Boucot (Brentford, Middlesex, United Kingdom), F. Maltais (Québec, QC, Canada), L. Tombs (Brentford, Middlesex, United Kingdom), C. Compton (Brentford, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), P. Jones (Brentford, Middlesex, United Kingdom)
| |
Inhaled corticosteroid use and its association with Pseudomonas aeruginosa infection in COPD
H. Shafiek (Alexandria, Egypt), J. Verdú (Palma de Mallorca, Spain), C. López-Causapé (Palma de Mallorca, Spain), A. Iglesias (Palma de Mallorca, Spain), L. Ramon-Clar (Palma de Mallorca, Spain), C. Juan (Palma de Mallorca, Spain), N. Toledo-Pons (Palma de Mallorca, Spain), A. Oliver (Palma de Mallorca, Spain), B. García Cosío Piqueras (Palma de Mallorca, Spain)
| |
Are COPD prescription patterns aligned with guidelines? a population-based study
T. Bahremand (Vancouver, Canada), M. Etminan (Vancouver, Canada), N. Roshan-Moniri (Vancouver, Canada), M. A. De Vera (Vancouver, Canada), H. Tavakoli (Vancouver, Canada), M. Sadatsafavi (Vancouver, Canada)
| |
Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy
V. Neches (Madrid, Spain), L. Vallejo-Aparicio (Madrid, Spain), A. Ismaila (Collegeville, United States of America), A. Sicras-Mainar (Barcelona, Spain), A. Sicras-Navarro (Barcelona, Spain), C. González (Valencia, Spain), R. Cuervo (Madrid, Spain), S. Shukla (Collegeville, United States of America), M. Garcia-Peñuela (Madrid, Spain)
| |